Integrative Ayurvedic Management of Lennox–Gastaut Syndrome in a Paediatric Patient: A Case Report

Background: Lennox–Gastaut Syndrome (LGS) is a severe, drug-resistant epileptic encephalopathy characterised by multiple seizure types, cognitive impairment, and psychomotor regression. Conventional management often provides incomplete control, prompting exploration of integrative therapeutic strategies. Case Presentation: An eleven-year-old boy with symptomatic LGS secondary to bilateral parieto-occipital gliosis presented with frequent daily seizures (atonic and tonic), cognitive deficits, behavioural disturbances, and delayed adaptive functioning. The child had a history of neonatal hypoglycemic brain injury, sepsis, and maternal epilepsy with hyperemesis gravidarum. Intervention: A comprehensive Ayurvedic treatment protocol was individualized based on dosas, duṣyas, agni-bala, deha-bala, vāyas, and sama–nirāma avasthā and given as an add on to existing antiepileptic drugs. Internal medications included Kūśmāṇḍa Swarasa Ghṛta, Avipathy Chūrṇa, Manasamitra Vātakā, and Gorocandī Guṭikā. External therapies included Kāḍi-kizhi, Takra-dhārā, Abhyanga, Kṣīra-dhārā, Śirodhārā, and Śirolepa with Balahatādi, Kṣīrabala, and Brahmi-sohalādi formulations, targeting vāta-pitta pacification, srotoshodhana, and mastulunga-majjā support. Outcome: Post-intervention, seizure frequency decreased from 6–7/day to 2–4/day and duration from 10–20 seconds to 5–10 seconds. Hague Seizure Severity Scale score improved from 44 to 25. Adaptive functioning improved as per Vineland Adaptive Behaviour Scale (VABS) with ABC score increasing from 40 to 47–48, including improvements in communication, socialisation, motor skills, and activities of daily living. Conclusion: A holistic, individualised Ayurvedic approach showed clinically meaningful improvements in seizure control and adaptive functioning in a child with chronic, refractory LGS. Integrative therapy targeting doṣa-specific pacification, neuro-restoration, and channel purification may provide benefit in paediatric drug-resistant epileptic syndromes.